WSL
CYT

Western Standard LLC’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Western Standard LLC’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-524,050
Closed -$1.36M – 38
2023
Q2 		$1.36M Buy
+524,050
New +$1.1M 1.17% 15

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
VAS
VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

Western Standard LLC's CYT Position: Q3 2023 in Review

Western Standard LLC sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2023, closing a stake of 524,050 shares — an estimated $1.36M sold.

Western Standard LLC first reported a position in CYT in Q2 2023 and held it in 1 quarter. The position peaked at $1.36M in Q2 2023. 41 funds tracked by Wall St. Rank hold CYT as of Q3 2023.

  • Western Standard LLC reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Western Standard LLC sold 524,050 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.36M.
  • Western Standard LLC first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • Western Standard LLC's Cyteir Therapeutics, Inc. Common Stock position peaked at $1.36M in Q2 2023.
  • 41 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Western Standard LLC's 13F filing for Q3 2023, filed 14 Nov 2023.